ArticleBMC psychiatry2026
Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intranasal administration in modulating depressive-like behavior and reconstructing treatment paradigms through neuroinflammation and neurotrophic pathways.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntranasal esketamine has recently emerged as an innovative treatment option for treatment-resistant depression (TRD). This retrospective, uncontrolled study aimed to evaluate the real-world effectiveness of esketamine in an naturalistic inpatient setting and explore demographic and clinical factors associated with treatment response.
methodsWe conducted a chart review of 101 inpatients with TRD treated with intranasal esketamine at the University Hospital Münster, Germany. Depression severity was assessed pretreatment and posttreatment with the Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck’s Depression Inventory-II (BDI-II). Repeated measures ANOVAs and logistic regression models were applied to identify treatment outcomes and associated factors.
resultsPatients (mean age 47.7 years; 51.5% women) presented with severe depression and frequent psychiatric comorbidities. Esketamine treatment led to significant improvements in MADRS (mean reduction − 10.7, p < 0.001) and BDI-II scores (mean reduction − 11.5, p < 0.001), with large effect sizes. Suicidality scores decreased significantly as well. Overall, 28.8% achieved response, 52.5% at least partial response, and 19.3% remission. Older age was associated with higher remission likelihood (OR 4.06, p = 0.041), while male gender was associated with partial response (OR 3.71, p = 0.012). Extended induction beyond eight sessions was particularly beneficial for older patients and those with psychiatric comorbidities. No treatment-related serious adverse events were observed.
conclusionsIn this large real-world inpatient cohort, intranasal esketamine significantly improved depression severity. Older patients and those with comorbid psychiatric disorders may particularly benefit from extended induction treatment. These findings support intranasal esketamine as an effective therapeutic option in TRD while highlighting the need for further controlled studies to refine patient selection and optimize treatment protocols. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.